We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
Read MoreHide Full Article
Key Takeaways
Natera launched a proprietary AI platform integrating multimodal oncology datasets and a core model.
The platform powers tools like a Digital Patient Simulator, Real-Time Trial Matching, and NeoPredict.
Early pilot results show strong performance, boosting treatment optimization and trial efficiency.
Natera, Inc. (NTRA - Free Report) recently unveiled its proprietary AI foundation model platform, marking a significant step in advancing precision oncology. Built entirely in-house, the platform integrates one of the largest longitudinal, multimodal oncology datasets with a billion-parameter core model designed to drive discovery across biomarker development, patient stratification, and therapeutic response prediction.
The platform also introduces AI-driven applications such as a Digital Patient Simulator, Real-Time Trial Matching, and NeoPredict, aimed at improving treatment optimization, trial efficiency, and immunotherapy response prediction. Early pilot results have demonstrated strong performance, highlighting the potential of this technology to transform clinical decision-making and enhance patient outcomes in oncology.
Likely Trend of NTRA Stock Following the News
Following the announcement, the company's shares gained 2.3% at Friday’s market closing. Shares of the company have gained 4.6% in the year-to-date period compared with the industry’s 0.9% growth. The S&P 500 has gained 9.8% in the same time frame.
In the long run, Natera’s AI foundation model platform can strengthen its business by creating high-value applications that enhance drug development, accelerate clinical trial recruitment, and improve treatment personalization. By leveraging its massive proprietary datasets and in-house AI models, Natera can deepen partnerships with pharmaceutical companies, generate new revenue streams from licensing and collaborations, and reinforce its leadership in precision oncology, ultimately driving sustainable growth and long-term market differentiation.
NTRA currently has a market capitalization of $22.7 billion. The company projects an earnings growth of 70% for the next year.
Image Source: Zacks Investment Research
More on NTRA’s Proprietary AI Foundation Model Platform
Natera’s newly launched AI foundation model platform is built on one of the largest longitudinal, multimodal oncology datasets assembled for AI training. The data foundation layer includes de-identified information from more than 250,000 tumor exomes and over 1 million longitudinal plasma timepoints, supplemented with clinical records, treatment histories, digital imaging, expression profiling, and outcomes data. This comprehensive and high-fidelity dataset enables scalable model development that is optimized for precision medicine applications.
At the core of the platform lies a billion-parameter AI foundation model trained on de-identified datasets from Natera’s Signatera and Altera products. The model integrates genomic, clinical, and imaging modalities to advance research across biomarker development, patient stratification, and therapeutic response prediction. This architecture is designed to accelerate discovery in oncology and related domains by unifying multiple data types into a single robust framework.
On the application side, the platform offers AI-driven tools aimed at improving both clinical decision-making and drug development. These include a Digital Patient Simulator to virtually model patient outcomes and optimize treatment choices, a Real-Time Trial Matching engine to accelerate trial recruitment and simulate virtual studies, and NeoPredict, an algorithm designed to forecast individual immunotherapy responses. Early pilot programs have already demonstrated strong performance, including superior accuracy over traditional metrics in predicting immunotherapy outcomes, underscoring the potential of these applications to drive adoption and long-term business impact.
Favorable Industry Prospects for NTRA
Per a report by Grand View Research, the global AI in healthcare market size was estimated at $26.57 billion in 2024 and is projected to reach $187.69 billion by 2030, registering a CAGR of 38.62% from 2025 to 2030.
A key factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy, and better patient outcomes.
NTRA’s Zacks Rank & Key Picks
Currently, NTRA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Natera Shares Rise on the Launch of AI Platform for Precision Oncology
Key Takeaways
Natera, Inc. (NTRA - Free Report) recently unveiled its proprietary AI foundation model platform, marking a significant step in advancing precision oncology. Built entirely in-house, the platform integrates one of the largest longitudinal, multimodal oncology datasets with a billion-parameter core model designed to drive discovery across biomarker development, patient stratification, and therapeutic response prediction.
The platform also introduces AI-driven applications such as a Digital Patient Simulator, Real-Time Trial Matching, and NeoPredict, aimed at improving treatment optimization, trial efficiency, and immunotherapy response prediction. Early pilot results have demonstrated strong performance, highlighting the potential of this technology to transform clinical decision-making and enhance patient outcomes in oncology.
Likely Trend of NTRA Stock Following the News
Following the announcement, the company's shares gained 2.3% at Friday’s market closing. Shares of the company have gained 4.6% in the year-to-date period compared with the industry’s 0.9% growth. The S&P 500 has gained 9.8% in the same time frame.
In the long run, Natera’s AI foundation model platform can strengthen its business by creating high-value applications that enhance drug development, accelerate clinical trial recruitment, and improve treatment personalization. By leveraging its massive proprietary datasets and in-house AI models, Natera can deepen partnerships with pharmaceutical companies, generate new revenue streams from licensing and collaborations, and reinforce its leadership in precision oncology, ultimately driving sustainable growth and long-term market differentiation.
NTRA currently has a market capitalization of $22.7 billion. The company projects an earnings growth of 70% for the next year.
Image Source: Zacks Investment Research
More on NTRA’s Proprietary AI Foundation Model Platform
Natera’s newly launched AI foundation model platform is built on one of the largest longitudinal, multimodal oncology datasets assembled for AI training. The data foundation layer includes de-identified information from more than 250,000 tumor exomes and over 1 million longitudinal plasma timepoints, supplemented with clinical records, treatment histories, digital imaging, expression profiling, and outcomes data. This comprehensive and high-fidelity dataset enables scalable model development that is optimized for precision medicine applications.
At the core of the platform lies a billion-parameter AI foundation model trained on de-identified datasets from Natera’s Signatera and Altera products. The model integrates genomic, clinical, and imaging modalities to advance research across biomarker development, patient stratification, and therapeutic response prediction. This architecture is designed to accelerate discovery in oncology and related domains by unifying multiple data types into a single robust framework.
On the application side, the platform offers AI-driven tools aimed at improving both clinical decision-making and drug development. These include a Digital Patient Simulator to virtually model patient outcomes and optimize treatment choices, a Real-Time Trial Matching engine to accelerate trial recruitment and simulate virtual studies, and NeoPredict, an algorithm designed to forecast individual immunotherapy responses. Early pilot programs have already demonstrated strong performance, including superior accuracy over traditional metrics in predicting immunotherapy outcomes, underscoring the potential of these applications to drive adoption and long-term business impact.
Favorable Industry Prospects for NTRA
Per a report by Grand View Research, the global AI in healthcare market size was estimated at $26.57 billion in 2024 and is projected to reach $187.69 billion by 2030, registering a CAGR of 38.62% from 2025 to 2030.
A key factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy, and better patient outcomes.
NTRA’s Zacks Rank & Key Picks
Currently, NTRA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.